Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2023-04-06 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
关于举行2022年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and arrangements for a 2022 annual performance explanation meeting (业绩说明会) to be held on April 14, 2023. It references that the 2022 Annual Report has already been disclosed on March 30, 2023, and this document is to inform investors about the upcoming performance explanation meeting, including how to participate and submit questions. The document is short (818 characters) and does not contain financial statements or detailed financial data itself. It is not the Annual Report (10-K) or the performance explanation meeting transcript (CT), but rather an announcement about the meeting. Therefore, it fits best under Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, or possibly AGM Information (AGM-R) if it were an AGM. However, since it is specifically a performance explanation meeting (业绩说明会), which is a form of investor presentation, the best fit is Investor Presentation (IP). Confidence is high given the clear description and document length.
2023-04-06 Chinese
华兰生物工程股份有限公司内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified public accounting firm and addresses the effectiveness of internal control over financial reporting as of December 31, 2022. The content includes auditor responsibilities, inherent limitations of internal control, and an audit opinion on the effectiveness of internal controls. The document is a standalone audit report focused on internal control audit results, not a full annual report or financial statement. It matches the description of an Audit Report / Information (AR) filing, which includes standalone audit reports and applied accounting principles. The document length is 1276 characters, which is sufficient for an audit report but too short for a full annual report. There is no indication that this is merely an announcement or certification letter, so it is not classified as RNS or RPA. FY 2022
2023-03-29 Chinese
年度股东大会通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2022 Annual General Meeting (AGM) of 华兰生物工程股份有限公司, including the date, time, location, voting procedures, agenda items, and proxy forms. It does not contain the actual annual report, financial statements, or voting results, but rather the announcement and instructions for the AGM. The document length is about 5523 characters, which is consistent with a detailed meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2023-03-29 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding the review and approval of various reports and proposals related to the 2022 fiscal year, including the Supervisory Board's work report, the 2022 annual report and summary, the 2022 financial statements, profit distribution plan, internal control self-evaluation report, investment proposals, and audit firm reappointment. The document states that these reports have been reviewed and will be submitted to the 2022 Annual General Meeting for approval. It also references that the full annual report and other detailed reports are published separately on official disclosure platforms. The document itself is a meeting resolution announcement and does not contain the full annual report or detailed financial statements but rather the Supervisory Board's approval and opinions on these reports. The document length is relatively short (2225 characters) and it serves as an official announcement of the Supervisory Board meeting resolutions. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not the full Annual Report (10-K) or Audit Report (AR).
2023-03-29 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the eighth board of directors' fifth meeting of 华兰生物工程股份有限公司. It includes approvals of various reports such as the 2022 annual report, financial statements, profit distribution plan, internal control self-evaluation report, social responsibility report, and appointment of the audit firm. The document also references that these reports are published elsewhere (on the cninfo.cn website) and that these resolutions will be submitted to the 2022 annual general meeting for approval. The document is not the reports themselves but a board meeting resolution announcement regarding these reports and related matters. It is not a full annual report (10-K), nor a simple announcement of report publication (RPA), but a board/management information disclosure about board meeting decisions. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 2848 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report.
2023-03-29 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2022 by 华兰生物工程股份有限公司. It discusses the company's internal control evaluation, including financial and non-financial internal control effectiveness, governance, organizational structure, and compliance with regulatory requirements. The document contains detailed explanations of internal control scope, evaluation criteria, and conclusions about the absence of major deficiencies. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. It does not appear to be an announcement or a brief summary but a substantive report on internal control. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations. FY 2022
2023-03-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.